Patiromer enables optimal medical therapy, prevention of hyp
Patiromer, a novel potassium binder, was associated with reduced hyperkalemia in patients with HFrEF, which enabled an increase in adherence to optimal medical therapy.

The DIAMOND trial included 878 patients (mean age, 67 years; 27% women) with NYHA class II to IV HF and EF < 40% who were on beta-blockers or unable to tolerate them and had past or present hyperkalemia (> 5 mEq/L). The primary endpoint was adjusted mean change in serum potassium to the end of the study.

Among the cohort, 360 patients from the patiromer group and 367 patients from the placebo group completed the blinded study treatment. The rate of hyperkalemia of > 5.5 mEq/L was lower in the patiromer group than the placebo group. The researchers found a lot of patients can be helped, particularly with using mineralocorticoid receptor antagonists, and there seemed to be a beneficial effect on maintaining normal potassium levels.